HRMY
Harmony Biosciences Holdings, Inc.Healthcare · $2.3B market cap
Verdict
Share price
$39.64
close of Oct 3, 2026
Fair value
$33.48
Sticker Price
Payback Price
$13.39
buy price
HRMY is Overpriced: at $39.64 it trades 18% above its fair value of $33.48. Its buy price (Payback Price) is $13.39, 66% below today's price. Business quality is strong: all 5 key numbers clear the 10% bar.
How we valued it
Buffett Normalized. A profitable, growing business, so we project its earnings 10 years ahead and work out what that is worth today.
Business quality
5 of 5 clear the 10% bar. What are the Big Five?
Follow HRMY
Get notified when it reaches its buy price of $13.39. Free.
Create a free accountInsider activity
Since Sep 4, 2026: no open-market purchases, 4 sales worth $1.5M and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Budur Kumar
CHIEF MEDICAL OFFICER · 2026-09-08
Sold
$989K
Budur Kumar
CHIEF MEDICAL OFFICER · 2026-09-08
Sold
$43K
Budur Kumar
CHIEF MEDICAL OFFICER · 2026-09-08
Sold
$190K
Budur Kumar
CHIEF MEDICAL OFFICER · 2026-09-04
Sold
$231K
Other filings
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works